

University of Groningen

Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues

Bodei, Lisa

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2009

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Bodei, L. (2009). Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

*PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH
RADIOLABELLED SOMATOSTATIN ANALOGUES*

The work presented in this thesis has started at the European Institute of Oncology, Milano, where most of work has been performed. Some articles have been made in collaboration with “Sapienza” University of Roma and University Medical Center Groningen.

ISBN: 978-90-367-3770-8 (book version)
ISBN: 978-90-367-3769-2 (digital version)

Cover picture:
Giandomenico Tiepolo
The Procession of the Trojan Horse in Troy
Oil on Canvas, The National Gallery, London

© 2008 Lisa Bodei

The printing of this thesis was financially supported by: **PerkinElmer Inc.**

RIJKSUNIVERSITEIT GRONINGEN

*PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH
RADIOLABELLED SOMATOSTATIN ANALOGUES*

Proefschrift

ter verkrijging van het doctoraat in de
Medische Wetenschappen
aan de Rijksuniversiteit Groningen
op gezag van de
Rector Magnificus, dr. F. Zwarts,
in het openbaar te verdedigen op
woensdag 6 mei 2009
om 14.45 uur

door

Lisa Bodei

geboren op 12 juli 1969
te Pisa, Italië

Promotores:

Prof.dr. R.A.J.O. Dierckx

Prof.dr. A. Signore

Copromotor:

Dr. G. Paganelli

Beoordelingscommissie:

Prof.dr. E.P. Krenning

Prof.dr. C. Van de Wiele

Prof.dr. B.H. Wolffenbuttel

To my family

INDEX

- 1- Introduction: neuroendocrine tumours (*J Endocrinol Invest* 2009, *in press*)
- 2- Peptide receptor therapies in NET (*J Endocrinol Invest* 2009, *in press*)
- 3- In vivo and in vitro detection of dopamine D2 receptors in uveal melanomas (*Cancer Biother & Radioph* 2003;18(6):895-902)
- 4- Dopamine receptor expression and function in corticotroph ectopic tumors (*J Clin Endocrinol Metab.* 2006 Oct 10; 2007 Jan;92(1):65-9)
- 5- Receptor-mediated radiotherapy with ^{90}Y -DOTA-D-Phe¹-Tyr³-octreotide (*Eur J Nucl Med* 2001 Apr;28(4):426-34)
- 6- Receptor-mediated radionuclide therapy with ^{90}Y -DOTATOC in association with amino acid infusion: a phase I study (*Eur J Nucl Med* 2003;30:207–216)
- 7- Receptor radionuclide therapy with ^{90}Y -DOTATOC in patients with medullary thyroid carcinomas (*Cancer Biother & Radioph* 2004;19(1):65-71)
- 8- Receptor radionuclide therapy with ^{90}Y -[DOTA]⁰-Tyr³-octreotide (^{90}Y -DOTATOC) in neuroendocrine tumours (*Eur J Nucl Med Mol Imaging* 2004; 7:1038-1046)
- 9- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ^{90}Y -DOTATOC and ^{177}Lu -DOTATATE: the role of associated risk factors (*Eur J Nucl Med Mol Imaging* 2008;35(10):1847-56)
- 10- Future perspectives and conclusions
- 11- Summary
- 12- Curriculum vitae et studiorum
- 13- Acknowledgements